Pradaxa

RSS

dabigatran etexilate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Pradaxa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pradaxa.

This EPAR was last updated on 15/06/2018

Authorisation details

Product details
Name
Pradaxa
Agency product number
EMEA/H/C/000829
Active substance
Dabigatran etexilate mesilate
International non-proprietary name (INN) or common name
dabigatran etexilate
Therapeutic area (MeSH)
  • Arthroplasty, Replacement
  • Venous Thromboembolism
Anatomical therapeutic chemical (ATC) code
B01AE07
Publication details
Marketing-authorisation holder
Boehringer Ingelheim International GmbH
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
17/03/2008
Contact address
D-55216 Ingelheim am Rhein
Germany

Product information

06/06/2018 Pradaxa - EMEA/H/C/000829 - II/0108

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total-hip-replacement surgery or total-knee-replacement surgery.

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more of the following risk factors:

  • previous stroke, transient ischaemic attack or systemic embolism;
  • left ventricular ejection fraction < 40%;
  • symptomatic heart failure ≥ New York Heart Association (NYHA) class 2;
  • age ≥ 75 years;
  • age ≥ 65 years associated with one of the following: diabetes mellitus, coronary artery disease or hypertension.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
2 ratings
2 ratings